These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity. Schiff D Neuro Oncol; 2016 Jun; 18(6):755-6. PubMed ID: 27174998 [No Abstract] [Full Text] [Related]
4. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Chen R; Cohen AL; Colman H Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978 [TBL] [Abstract][Full Text] [Related]
5. Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Ahluwalia MS; Patel M; Peereboom DM Expert Rev Anticancer Ther; 2011 Nov; 11(11):1739-48. PubMed ID: 22050023 [TBL] [Abstract][Full Text] [Related]
6. [Inhibition of cellular adhesion and invasion in gliomas]. Sasaki H; Yoshida K Nihon Rinsho; 2005 Sep; 63 Suppl 9():68-73. PubMed ID: 16201502 [No Abstract] [Full Text] [Related]
15. Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas? Lee EQ; McFaline-Figueroa JR; Cloughesy TF; Wen PY Neuro Oncol; 2018 Jul; 20(8):1144. PubMed ID: 29955870 [No Abstract] [Full Text] [Related]
18. Chemotherapy for treatment of grade II gliomas. Strowd RE; Holdhoff M; Grossman SA Oncology (Williston Park); 2014 Dec; 28(12):1036-43. PubMed ID: 25510803 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection. Wu J; Kim C; Bai HX; Tang L; Wang Y; Li X; Zhang Z; Karakousis G; Huang R; Zhang PJ; Xiao B; Yang L World Neurosurg; 2019 Feb; 122():e108-e120. PubMed ID: 30261385 [TBL] [Abstract][Full Text] [Related]